NCT01263691View on ClinicalTrials.gov

Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

June 30, 2012

Conditions
Bacillus Anthracis (Anthrax) Infection
Interventions
BIOLOGICAL

BioThrax

BioThrax

BIOLOGICAL

AV7909 Formulation 1

AV7909 Formulation 1

BIOLOGICAL

AV7909 Formulation 2

AV7909 Formulation 2

BIOLOGICAL

AV7909 Formulation 3

AV7909 Formulation 3

BIOLOGICAL

AV7909 Formulation 4

AV7909 Formulation 4

DRUG

Control

Saline control

Trial Locations (3)

27607

North Carolina Clinical Research, Raleigh

33143

Miami Research Associates, Miami

84124

Jean Brown Research, Salt Lake City

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Department of Health and Human Services

FED

lead

Emergent BioSolutions

INDUSTRY